SAN DIEGO, CA - Apr 3, 2019 - ~~BINDING SITEs IMMUNOLOGICALS GROUP is pleased to announce the addition of three (3) new native Bordetella pertussis antigens to its broad offering of products for in-vitro diagnostic (IVD) manufacturing and research applications. The Bordetella pertussis Filamentous Hemagglutinin Antigen (FHA), Bordetella pertussis Toxin Antigen, and Bordetella pertussis Whole-Cell Antigen have all been expressly designed for use as integral components within solid phase enzyme immunoassay test procedures, especially ELISA. As such, the availability of these antigens is certain to benefit the needs of biopharmaceutical, clinical, drug-discovery, and life science researchers, as well as manufacturers of IVD test kits.
All of the antigens offered exhibit exceptional purity levels as a result of exclusive chromatographic manufacturing techniques, while demonstrating exceptional lot-to-lot consistencies and high degrees of activity and specificity. They all feature an outstanding shelf life stability claim of ten (10) years from the date of manufacture and are offered in a standard-sized 1.0mg filled vial, with larger, bulk packaging configurations also being available. Evaluation samples for testing are also available upon request.
BINDING SITEs IMMUNOLOGICALS GROUP serves the in-vitro diagnostic (IVD) manufacturing and biopharmaceutical | clinical | life-science | medical research markets with a comprehensive line of innovative products. For additional information, contact The Binding Site, Inc. at 6730 Mesa Ridge Road, San Diego, CA 92121 USA. Phone: 800-633-4484; FAX: 858-453-9189; Email: email@example.com. Please visit our website at www.immunologicals.com.